Skip to content Skip to footer
Viewpoints_Dipal Doshi

PharmaShots Interview: Entrada’s Dipal Doshi Shares Insights on the Series B Funding Utilize to Advance DMD Program into the Clinic

In an interview with PharmaShots, Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics share his views on $116M Series B financing and what does this milestone means for the company's pipeline. Shots: The Series B financing was led by Wellington Management Company, who was joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]